

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

| | |
|-----------------------|--------------------------|
| Name of entity | EVE Health Group Limited |
| ABN | 89 106 523 611 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|-------------------------|
| Name of Director | Alasdair Campbell Cooke |
| Date of last notice | 1 June 2020 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| Direct or indirect interest | Direct and Indirect |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | Glenlaren Pty Ltd Hartree Pty Ltd Mitchell River Group Pty Ltd Melissa Louise Cooke (Spouse) |
| Date of change | 31 December 2021 |
| No. of securities held prior to change | Direct 67,360,212 Ordinary Shares 1,500,000 Performance Rights 3,500,000 Unlisted option exercisable at \$0.006 by 31 December 2021 |
| | Indirect 118,514,389 Ordinary Shares |
| Class | Unlisted option exercisable at \$0.006 by 31 December 2021 |
| Number acquired | - |
| Number disposed | 3,500,000 |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | - |
| No. of securities held after change | Direct 67,360,212 Ordinary Shares 1,500,000 Performance Rights |
| | Indirect 118,514,389 Ordinary Shares |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Expiry of option |

Appendix 3Y
Change of Director's Interest Notice

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

| | |
|--|--|
| Detail of contract | |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | |
| Interest after change | |

Part 3 – *Closed period

| | |
|--|-----|
| Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

| | |
|-----------------------|--------------------------|
| Name of entity | EVE Health Group Limited |
| ABN | 89 106 523 611 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|--------------------|
| Name of Director | George Cameron-Dow |
| Date of last notice | 1 June 2020 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|---|
| Direct or indirect interest | Direct and Indirect |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | Dhow Nominees Pty Ltd ATF Dhow Trust |
| Date of change | 31 December 2021 |
| No. of securities held prior to change | Direct 1,500,000 Performance Rights Indirect 7,999,980 Ordinary Shares 2,000,000 Unlisted option exercisable at \$0.006 by 31 December 2021 |
| Class | Unlisted option exercisable at \$0.006 by 31 December 2021 |
| Number acquired | - |
| Number disposed | 2,000,000 |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small> | - |
| No. of securities held after change | Direct 1,500,000 Performance Rights Indirect 7,999,980 Ordinary Shares |
| Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | Expiry of option |

Appendix 3Y
Change of Director's Interest Notice

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

| | |
|--|--|
| Detail of contract | |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | |
| Interest after change | |

Part 3 – *Closed period

| | |
|--|-----|
| Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

| | |
|-----------------------|--------------------------|
| Name of entity | EVE Health Group Limited |
| ABN | 89 106 523 611 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|---------------------|
| Name of Director | Gregory William Fry |
| Date of last notice | 26 November 2021 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|--|
| Direct or indirect interest | Direct and Indirect |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | The Fry Family Superfund Abigail Fry (spouse) |
| Date of change | 29-31 December 2021 |
| No. of securities held prior to change | Direct 4,141,667 Ordinary Shares 18,000,000 Performance Rights 3,333,332 Unlisted options exercisable at \$0.006 by 31 December 2021 16,000,000 Unlisted options exercisable at \$0.016 by 26 November 2024 |
| | Indirect 27,788,066 Ordinary Shares (Super Fund) 45,760,124 Ordinary Shares (Abigail Fry) |
| Class | Ordinary Shares |
| Number acquired | 1,800,000 Ordinary Shares (Super Fund) |
| Number disposed | 3,333,332 Unlisted options exercisable at \$0.006 by 31 December 2021 |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small> | \$7,200 |
| No. of securities held after change | Direct 4,141,667 Ordinary Shares 18,000,000 Performance Rights 16,000,000 Unlisted options exercisable at \$0.016 by 26 November 2024 |
| | Indirect 29,588,066 Ordinary Shares (Super Fund) 45,760,124 Ordinary Shares (Abigail Fry) |

Appendix 3Y
Change of Director's Interest Notice

| | |
|---|--|
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | On market acquisition and expiry of option |
|---|--|

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

| | |
|--|--|
| Detail of contract | |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | |
| Interest after change | |

Part 3 – *Closed period

| | |
|--|-----|
| Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |